^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Targeted therapy or immunotherapy for advanced or metastatic disease...PD-L1≥1%...first-line therapy...Carboplatin/paclitaxel/bevacizumab/ atezolizumab (nonsquamous)
Secondary therapy:
carboplatin + paclitaxel
Source:
Title:
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Studio randomizzato di fase II di confronto tra atezolizumab versus atezolizumab più bevacizumab come trattamento di prima linea in pazienti con sovraespressione di PD-L1 con carcinoma polmonare non a piccole cellule avanzato
Excerpt:
...1) Histologically confirmed diagnosis of stage IV non-squamous NSCLC with no evidence of EGFR sensitizing mutations or ALK or ROS1 rearrangements.2) Availability of tumor tissue.3) 3) Evidence of high levels of PD-L1 expression evaluated with immunohistochemistry (=50% by 22C3 or SP263 or TC/IC 3 scoring by SP 142) .4) No previous chemotherapy. ...
Trial ID:
Source:
Title:
A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR gene Un ensayo que explora la eficacia (qué tan bien funciona el tratamiento) y la tolerabilidad de la combinación de dos fármacos en investigación (atezolizumab y bevacizumab), cuando se administra junto con uno de dos tratamientos de quimioterapia diferentes, en pacientes con cáncer de pulmón de células no pequeñas y mutaciones específicas (cambios) en el gen EGFR
Excerpt:
...- Objective response - Extra-cranial PFS- Intracranial PFS- Overall survival, including OS rate at 12 months- Adverse events according to CTCAE v5.0- Patient reported quality of life- prior use of 3rd generation TKI, EGFR mutation subtype and PD-L1 expression- Sequencing of specific gene panels- Tumour mutation burden- Microbiome analysis - Respuesta objetiva- PFS extracraneal- SLP intracraneal- Supervivencia general, incluida la tasa de SG a los 12 meses- Eventos adversos según CTCAE v5.0- Calidad de vida del paciente- Uso previo de TKI de tercera generación, subtipo de mutación EGFR y expresión de PD-L1- Secuenciación de paneles genéticos específicos- Carga de mutación tumoral- Análisis de microbiomas...
Trial ID:
More C2 evidence
Source:
Title:
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
Excerpt:
...PD-L1 expression of ≥1% as documented through central testing of a representative tumor tissue specimen either from previously obtained archival tumor tissue or tissue obtained from a biopsy at screening...
Source:
Title:
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Excerpt:
...PD-L1 positive is defined as a tumor proportion score (TPS) ≥ 1%....
Trial ID:
Source:
Title:
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
Excerpt:
...Evidence of PD-L1 expression evaluated with immunohistochemistry (≥1%)....
Trial ID:
